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Background: Florbetapir is one of several 18F-labeled amyloid plaque imaging tracers for positron emission
tomography (PET). As the bio-distribution and radiation dose of PET tracers in human research are
important for estimating the relative risks and benefits, a study was conducted to obtain this information
on florbetapir.
Methods: Nine cognitively normal subjects (six females and three males, age 58 ± 10 years, weight 81 ± 17 kg)
received an intravenous bolus injection of 395 ± 27.9 MBq of florbetapir, and whole-body emission scans were
performed over approximately 6 h. Computed tomography scans were acquired for attenuation correction.
Volumes of interest (VOIs) for source organs including the brain, liver, lung, heart wall, and vertebrae were
defined on the PET images. The VOIs of the gallbladder, urinary bladder, and large and small intestines were also
defined. Using reference man organ volumes (ICRP 30), total activity was calculated per organ for each time
point. The resultant time-activity curves (TACs) were fitted with constrained exponentials. Kinetic data were
entered into OLINDA/EXM software to calculate dose estimates; the dynamic urinary bladder and ICRP 30 GI
tract models were employed. The effective dose (ED) for each subject was estimated from the acquired data
using the adult model.
Results: The mean ED determined for nine healthy volunteers was 18.60 ± 4.26 μSv/MBq or 6.88 mSv for a
370-MBq dose. The organs that received the highest radiation absorbed doses were the gallbladder, upper large
intestine, small intestine, liver, and urinary bladder at 143.0 ± 80.20, 74.50 ± 34.20, 65.50 ± 29.60, 64.40 ± 22.10,
and 27.10 ± 11.70 μSv/MBq, respectively.
Conclusions: The ED for florbetapir has been calculated for nine healthy volunteers. At a dose of 370 MBq
florbetapir, the total average ED is approximately 6.88 mSv.Background
Accumulation of amyloid-β (Aβ) fibrils in the form of
amyloid plaques is a neuropathological requirement
for definitive diagnosis [1]. Positron emission tomog-
raphy (PET) tracers that bind to aggregated Aβ pep-
tides offer promise to directly assess fibrillar amyloid
pathology in vivo [2,3]. The initial studies with 11C
Pittsburgh Compound B (PiB) were the first to clearly
demonstrate the feasibility of this approach [4]. How-
ever, the 20-min half-life of 11C limits the use of this
molecular imaging ligand to specialized research cen-
ters. To address this issue, several amyloid imaging* Correspondence: joshi@avidrp.com
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in any medium, provided the original work is pligands that use the longer-lived 18F PET isotope have
been developed [5].
One of these tracers is florbetapir F 18 ((E)-4(2-(6-
(2-(2-(2-[18F]fluoroehoxy)ethoxy)ethoxy)pyridine-3-yl)
vinyl)-N-mathylbenzeamine, also known as 18F-AV-45.
When applied at tracer concentrations, florbetapir la-
bels Aβ plaques in sections from patients with patho-
logically confirmed Alzheimer's disease (AD) [6], and
PET human studies show increased tracer retention
in the brains of those clinically diagnosed with AD [7].
A recently reported autopsy study demonstrated high
correspondence of florbetapir PET images to histopath-
ology [8,9]. The present study was carried out to assess
the radiation dosimetry of florbetapir.open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 CT and PET acquisition time sequence for all nine
volunteers: frame start time after injection in minutes
Session Subject number
009 001 012 007 008 010 002 006 003
Low-dose CT scan after positioning and before florbetapir injection
1.1 4 9 3 3 4 4 1 3 2
1.2 18 25 16 20 17 22 18 15 20
1.3 29 50 30 33 30 39 NA 26 37
1.4 47 64 45 46 46 55 52 39 NA
Short break <30 min
Low-dose CT scan after positioning
2.1 76 105 71 85 72 90 88 64 76
2.2 94 120 88 102 89 109 113 79 102
2.3 NA NA NA NA NA NA 133 NA NA
Low-dose CT scan after positioning
3.1 137 170 129 129 130 187 206 112 153
Low-dose CT scan after positioning
4.1 204 236 198 180 186 246 250 181 228
Low-dose CT scan after positioning
5.1 268 301 241 248 246 306 303 240 NA
Low-dose CT scan after positioning
6.1 326 363 NA NA 308 366 364 301 NA
Low-dose CT scan after positioning
7.1 384 428 NA 360 356 NA NA 361 NA
NA means that the subject is not imaged during that duration of the session.
PET scans are identified as session#.scan#.
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Subject population
Nine healthy, cognitively normal subjects (three males
and six females) with mean age of 58 ± 10 years and
mean weight of 81 ± 17 kg were recruited. The study
protocol was institutional review board (Biomed IRB,
San Diego, CA)-approved, and written informed con-
sent form was obtained from each subject enrolled.
PET imaging
A catheter was placed in an antecubital vein in the sub-
ject's arm for injecting the tracer. Subjects were posi-
tioned supine in a Biograph 40 TruePoint PET/CT
scanner (Siemens Medical Systems, Malvern, PA, USA)
with the arms at their sides. For the purpose of this
study, a whole-body (WB) scan was defined as a total
of seven bed positions from the subject's top of the
head to mid-thighs. Subjects wore an abdominal binder
during imaging to reduce respiratory motion between
PET and computed tomography (CT) acquisitions.
Once positioned, a low-dose whole-body CT scan was
obtained and then the subjects were injected with a
target dose of 370 MBq florbetapir (actual mean dose
395 ± 27.9 MBq). Following injection, a session of up
to four WB PET emission scans was acquired using the
initial CT without subject repositioning. Following a
short break (<30 min), a second low-dose CT was
taken followed immediately by a session of at least two
WB PET emission scans. Additional sessions consist-
ing of low-dose CT and PET emission scans were sub-
sequently obtained at roughly 60-min intervals for a
total of up to seven sessions with breaks between the
sessions for patient comfort. Each session included at
least one PET whole-body emission scan (seven bed
positions). The time per PET bed position was varied
from 90 s for the first session to 4 min for the final ses-
sion to compensate for radioactive decay.
In general, session 1 consisted of four PET scans, ses-
sion 2 consisted of two PET scans, and sessions 3, 4, 5,
6, and 7 consisted of one PET scan each. Although scan
data was obtained for an average of approximately 6 h
(range 4.25 to 7.37 h) for all subjects, to accommodate
subject comfort, some scans were omitted in some
subjects: For four of nine subjects, all 11 emission
scans were acquired; in three subjects, 10 emission
scans were acquired; in one subject, 9 emission scans
were acquired; and in one subject, the data were ac-
quired in 7 scans. The time required to reposition the
bed to initiate subsequent emission scans in a session
was variable, and patients were given periodic breaks
as requested. This resulted in variable start time across
the subjects and variable number of image sequences
(Table 1). The mean time for all subjects until the end
of the last scan was 5.95 ± 1.09 h.PET data post-processing
The acquired emission data were reconstructed using
iterative reconstruction (two iterations, eight subsets),
with attenuation, random, and scatter correction, and a
post-reconstruction Gaussian filter of 7 mm was ap-
plied. PET whole-body images were generated with a
matrix size of 128 × 128 per slice and a voxel size of
5.35 × 5.35 × 3 mm3. The camera sensitivity was cali-
brated using a uniform cylindrical phantom (dimen-
sions: 20-cm diameter, 30-cm length, and 9,420-mL
volume) filled with a known concentration of activity
to generate a camera-to-well counter cross-calibration
factor (approximately 1.1 (Bq/mL)/cps)) which was
subsequently applied to all PET measurement of in vivo
activity.
Dosimetry analysis
Following reconstruction, volumes of interest (VOIs) for
various body organs were defined on the PET images
for each patient. Based on the visual examination, the
anatomical information from the CT data and the hu-
man whole-body reference atlas [10,11] was used to
Figure 1 Time-activity curves showing mean count activity (Bq/cm3) over time in eight organs for a representative subject.
Mean radioactivity concentration values are different across the organs, so the upper limit of the scale is variable.
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VOI process were the brain, liver, lung, heart wall,
urinary bladder, vertebrae, intestine, and gallbladder.Using these regions on the PET emission data, average
counts for the organs were determined at each time
imaged. The regional activities were then calculated for
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(TAC) for each region of a given subject (Figure 1). All
organ TACs were fitted with one or two exponential
terms using SAAM II software [12]. Time integrals of
activity for all the organs were calculated from a lower
limit of zero to an upper limit of infinity and expressed
as the number of disintegrations in source organs [13].
These values were entered in OLINDA/EXM software
[14], using the adult model. Activity observed in a seg-
ment of the gastrointestinal (GI) tract was used to esti-
mate total intestinal excretion, using the ICRP 30 GI
kinetic model in the OLINDA/EXM software.
The cumulated activity in the urinary bladder contents
was determined by fitting the TAC of the bladder con-
tents with an exponential in-growth function of the
form:
U tð Þ ¼ U 0ð Þ  1−e−t=τ
 
ð1Þ
where U(t) is the fraction of activity in the bladder at
time ‘t’ after injection and τ is the half-life of 18F/ln [2].
These parameters were entered into the voiding blad-
der model of OLINDA/EXM. For the principal ana-
lysis, no bladder voiding was assumed. A separate
analysis was performed with no bladder void until
90 min post-injection.
Additional calculations were performed using the
feature in OLINDA/EXM that allows modification of4 17 30
246186130
Figure 2 Series of PET whole-body images from 4 to 356 min after indoses on body mass ratios to adjust the calculations to
be more appropriate for the subject's individual body
size. All organs and the whole body were selected and
scaled by ratios of the subject's body weight to that of
the reference phantom to develop dose estimates for
50-, 60-, and 80-kg individuals (the reference adult is
approximately 70 kg).Results
Figure 2 shows a typical series of PET scans in a
healthy volunteer enrolled in this study. The series of
images demonstrates rapid distribution of florbetapir
shortly following injection. Essentially, immediate up-
take into, followed by rapid clearance out of, the nor-
mal brain was seen. Rapid clearance from circulation
and localization in the liver was also observed. Some
accumulation was observed in the urinary bladder, but
primarily, the elimination appeared to occur by way of
clearance from the liver and excretion through the
gallbladder into the GI tract.
Cumulated activities in each organ were determined
for individual subjects to allow subject-specific dose esti-
mates to be determined. Based on the nine subject mea-
surements of florbetapir, the effective dose (ED) was
determined to be 18.60 ± 4.260 μSv/MBq or 6.88 mSv
for a 370-MBq dose with no specific assumptions re-
garding bladder voiding. In a separate analysis assuming
no urinary bladder voiding until 90 min, the ED was46 72 89
356308
jection of florbetapir F 18.
Table 2 Radiation dose estimates (μSv/MBq) with no urinary bladder voiding
Target organ 024-009 024-001 024-012 024-007 024-008 024-010 024-002 024-006 024-003 Average Std Dev
Adrenals 1.30E + 01 1.24E + 01 1.63E + 01 1.34E + 01 1.42E + 01 1.40E + 01 1.33E + 01 1.38E + 01 1.17E + 01 1.36E + 01 1.29E + 00
Brain 1.27E + 01 7.03E + 00 9.50E + 00 8.25E + 00 1.12E + 01 1.20E + 01 1.10E + 01 9.86E + 00 8.66E + 00 1.00E + 01 1.86E + 00
Breasts 6.76E + 00 6.87E + 00 6.66E + 00 6.98E + 00 4.61E + 00 6.73E + 00 5.09E + 00 5.78E + 00 6.65E + 00 6.24E + 00 8.65E − 01
Gallbladder wall 7.18E + 01 8.30E + 01 2.22E + 02 1.26E + 02 2.00E + 02 8.36E + 01 1.07E + 02 3.02E + 02 8.87E + 01 1.43E + 02 8.02E + 01
LLI wall 3.05E + 01 2.09E + 01 2.19E + 01 3.37E + 01 4.16E + 01 2.90E + 01 4.21E + 01 1.57E + 01 1.51E + 01 2.78E + 01 1.02E + 01
Small intestine 7.08E + 01 4.36E + 01 5.05E + 01 7.91E + 01 1.10E + 02 6.69E + 01 1.07E + 02 3.47E + 01 2.73E + 01 6.55E + 01 2.96E + 01
Stomach wall 1.22E + 01 1.13E + 01 1.22E + 01 1.31E + 01 1.17E + 01 1.22E + 01 1.19E + 01 1.04E + 01 1.03E + 01 1.17E + 01 9.06E − 01
ULI wall 7.96E + 01 4.86E + 01 5.79E + 01 8.93E + 01 1.27E + 02 7.56E + 01 1.22E + 02 4.02E + 01 3.00E + 01 7.45E + 01 3.42E + 01
Heart wall 1.35E + 01 1.06E + 01 1.41E + 01 1.18E + 01 1.55E + 01 1.46E + 01 1.35E + 01 1.27E + 01 1.14E + 01 1.31E + 01 1.59E + 00
Kidneys 1.28E + 01 1.19E + 01 1.46E + 01 1.37E + 01 1.38E + 01 1.33E + 01 1.33E + 01 1.24E + 01 1.09E + 01 1.30E + 01 1.11E + 00
Liver 4.63E + 01 4.18E + 01 9.81E + 01 4.81E + 01 9.25E + 01 6.42E + 01 7.57E + 01 7.41E + 01 3.89E + 01 6.44E + 01 2.21E + 01
Lungs 8.54E + 00 7.69E + 00 9.37E + 00 7.67E + 00 9.34E + 00 9.31E + 00 8.14E + 00 9.19E + 00 7.47E + 00 8.52E + 00 8.01E − 01
Muscle 9.36E + 00 8.87E + 00 8.70E + 00 9.77E + 00 7.60E + 00 9.19E + 00 8.23E + 00 7.56E + 00 8.36E + 00 8.63E + 00 7.62E − 01
Ovaries 1.93E + 01 1.50E + 01 1.50E + 01 2.11E + 01 2.24E + 01 1.86E + 01 2.34E + 01 1.16E + 01 1.23E + 01 1.76E + 01 4.34E + 00
Pancreas 1.37E + 01 1.31E + 01 1.70E + 01 1.47E + 01 1.51E + 01 1.45E + 01 1.40E + 01 1.50E + 01 1.23E + 01 1.44E + 01 1.34E + 00
Red marrow 1.67E + 01 1.26E + 01 1.33E + 01 1.44E + 01 1.66E + 01 1.51E + 01 1.56E + 01 1.28E + 01 1.19E + 01 1.43E + 01 1.78E + 00
Osteogenic cells 3.43E + 01 2.43E + 01 2.43E + 01 2.60E + 01 3.19E + 01 2.94E + 01 2.88E + 01 2.58E + 01 2.38E + 01 2.76E + 01 3.71E + 00
Skin 6.62E + 00 6.51E + 00 5.97E + 00 6.79E + 00 4.47E + 00 6.41E + 00 5.08E + 00 5.23E + 00 6.25E + 00 5.93E + 00 8.09E − 01
Spleen 9.73E + 00 9.53E + 00 9.06E + 00 1.02E + 01 7.28E + 00 9.51E + 00 7.96E + 00 7.86E + 00 8.99E + 00 8.90E + 00 9.86E − 01
Testes 7.75E + 00 7.84E + 00 6.44E + 00 8.20E + 00 4.37E + 00 7.51E + 00 5.93E + 00 5.62E + 00 7.66E + 00 6.81E + 00 1.29E + 00
Thymus 8.11E + 00 8.26E + 00 7.51E + 00 8.30E + 00 4.97E + 00 7.93E + 00 5.73E + 00 6.59E + 00 8.04E + 00 7.27E + 00 1.22E + 00
Thyroid 7.90E + 00 7.98E + 00 6.61E + 00 7.93E + 00 4.09E + 00 7.43E + 00 5.06E + 00 5.96E + 00 7.81E + 00 6.75E + 00 1.43E + 00
Urinary bladder wall 2.25E + 01 1.76E + 01 2.03E + 01 2.89E + 01 2.64E + 01 3.29E + 01 5.47E + 01 1.56E + 01 2.48E + 01 2.71E + 01 1.17E + 01
Uterus 1.68E + 01 1.38E + 01 1.35E + 01 1.85E + 01 1.80E + 01 1.67E + 01 2.03E + 01 1.08E + 01 1.22E + 01 1.56E + 01 3.19E + 00
Total body 1.22E + 01 1.07E + 01 1.22E + 01 1.22E + 01 1.23E + 01 1.22E + 01 1.22E + 01 1.04E + 01 9.96E + 00 1.16E + 01 9.51E − 01
Effective dose 1.90E + 01 1.49E + 01 1.77E + 01 2.01E + 01 2.44E + 01 1.98E + 01 2.49E + 01 1.43E + 01 1.27E + 01 1.86E + 01 4.26E + 00


















Table 3 Radiation dose estimates (μSv/MBq) assuming one urinary bladder void at 90 min post-injection
Target organ 24-009 24-001 24-012 24-007 24-008 24-010 24-002 24-006 24-003 Average Std Dev
Adrenals 1.30E + 01 1.24E + 01 1.63E + 01 1.34E + 01 1.42E + 01 1.40E + 01 1.33E + 01 1.38E + 01 1.17E + 01 1.36E + 01 1.29E + 00
Brain 1.27E + 01 7.03E + 00 9.50E + 00 8.25E + 00 1.12E + 01 1.20E + 01 1.10E + 01 9.86E + 00 8.66E + 00 1.00E + 01 1.86E + 00
Breasts 6.76E + 00 6.87E + 00 6.66E + 00 6.98E + 00 4.61E + 00 6.73E + 00 5.09E + 00 5.78E + 00 6.65E + 00 6.24E + 00 8.65E − 01
Gallbladder wall 7.18E + 01 8.30E + 01 2.22E + 02 1.26E + 02 2.00E + 02 8.35E + 01 1.07E + 02 3.02E + 02 8.87E + 01 1.43E + 02 8.02E + 01
LLI wall 3.03E + 01 2.09E + 01 2.18E + 01 3.37E + 01 4.15E + 01 2.88E + 01 4.20E + 01 1.57E + 01 1.50E + 01 2.77E + 01 1.02E + 01
Small intestine 7.07E + 01 4.36E + 01 5.04E + 01 7.91E + 01 1.10E + 02 6.69E + 01 1.07E + 02 3.47E + 01 2.73E + 01 6.55E + 01 2.96E + 01
Stomach wall 1.22E + 01 1.13E + 01 1.22E + 01 1.31E + 01 1.17E + 01 1.22E + 01 1.19E + 01 1.03E + 01 1.03E + 01 1.17E + 01 9.24E − 01
ULI wall 7.96E + 01 4.86E + 01 5.79E + 01 8.93E + 01 1.26E + 02 7.55E + 01 1.22E + 02 4.02E + 01 3.00E + 01 7.43E + 01 3.40E + 01
Heart wall 1.35E + 01 1.06E + 01 1.41E + 01 1.18E + 01 1.55E + 01 1.46E + 01 1.35E + 01 1.27E + 01 1.14E + 01 1.31E + 01 1.59E + 00
Kidneys 1.28E + 01 1.19E + 01 1.46E + 01 1.37E + 01 1.38E + 01 1.33E + 01 1.33E + 01 1.24E + 01 1.09E + 01 1.30E + 01 1.11E + 00
Liver 4.63E + 01 4.18E + 01 9.81E + 01 4.81E + 01 9.25E + 01 6.42E + 01 7.57E + 01 7.41E + 01 3.89E + 01 6.44E + 01 2.21E + 01
Lungs 8.54E + 00 7.69E + 00 9.37E + 00 7.67E + 00 9.34E + 00 9.31E + 00 8.14E + 00 9.18E + 00 7.47E + 00 8.52E + 00 7.99E − 01
Muscle 9.31E + 00 8.87E + 00 8.68E + 00 9.78E + 00 7.57E + 00 9.15E + 00 8.22E + 00 7.55E + 00 8.33E + 00 8.61E + 00 7.63E − 01
Ovaries 1.91E + 01 1.50E + 01 1.49E + 01 2.11E + 01 2.23E + 01 1.84E + 01 2.34E + 01 1.16E + 01 1.22E + 01 1.76E + 01 4.33E + 00
Pancreas 1.37E + 01 1.31E + 01 1.70E + 01 1.47E + 01 1.50E + 01 1.45E + 01 1.40E + 01 1.50E + 01 1.23E + 01 1.44E + 01 1.34E + 00
Red marrow 1.67E + 01 1.26E + 01 1.33E + 01 1.44E + 01 1.66E + 01 1.51E + 01 1.56E + 01 1.28E + 01 1.19E + 01 1.43E + 01 1.78E + 00
Osteogenic cells 3.43E + 01 2.43E + 01 2.43E + 01 2.60E + 01 3.19E + 01 2.94E + 01 2.88E + 01 2.58E + 01 2.38E + 01 2.76E + 01 3.71E + 00
Skin 6.60E + 00 6.51E + 00 5.96E + 00 6.79E + 00 4.46E + 00 6.39E + 00 5.08E + 00 5.23E + 00 6.24E + 00 5.92E + 00 8.07E − 01
Spleen 9.72E + 00 9.53E + 00 9.06E + 00 1.03E + 01 7.27E + 00 9.50E + 00 7.96E + 00 7.86E + 00 8.98E + 00 8.91E + 00 1.00E + 00
Testes 7.62E + 00 7.84E + 00 6.37E + 00 8.22E + 00 4.29E + 00 7.39E + 00 5.89E + 00 5.58E + 00 7.57E + 00 6.75E + 00 1.30E + 00
Thymus 8.11E + 00 8.26E + 00 7.51E + 00 8.30E + 00 4.97E + 00 7.93E + 00 5.73E + 00 6.59E + 00 8.04E + 00 7.27E + 00 1.22E + 00
Thyroid 7.90E + 00 7.98E + 00 6.61E + 00 7.93E + 00 4.09E + 00 7.43E + 00 5.06E + 00 5.96E + 00 7.81E + 00 6.75E + 00 1.43E + 00
Urinary bladder wall 1.54E + 01 1.76E + 01 1.65E + 01 2.98E + 01 2.21E + 01 2.67E + 01 5.28E + 01 1.38E + 01 2.01E + 01 2.39E + 01 1.21E + 01
Uterus 1.64E + 01 1.38E + 01 1.33E + 01 1.86E + 01 1.78E + 01 1.63E + 01 2.02E + 01 1.06E + 01 1.19E + 01 1.54E + 01 3.22E + 00
Total body 1.21E + 01 1.07E + 01 1.22E + 01 1.22E + 01 1.22E + 01 1.22E + 01 1.22E + 01 1.04E + 01 9.93E + 00 1.16E + 01 9.41E − 01
Effective dose 1.86E + 01 1.49E + 01 1.75E + 01 2.01E + 01 2.41E + 01 1.94E + 01 2.48E + 01 1.42E + 01 1.25E + 01 1.85E + 01 4.23E + 00


















Table 4 Average dose estimates (μSv/MBq) across nine healthy volunteers for 50-, 60-, and 80-kg scaled weights
Target organ 50 kg 60 kg 70 kg 80 kg
Average Std Dev Average Std Dev Average Std Dev Average Std Dev
Adrenals 1.75E + 01 1.65E + 00 1.52E + 01 1.38E + 00 1.36E + 01 1.30E + 00 1.23E + 01 1.22E + 00
Brain 1.33E + 01 2.51E + 00 1.14E + 01 2.13E + 00 1.00E + 01 1.86E + 00 9.01E + 00 1.67E + 00
Breasts 8.17E + 00 1.22E + 00 7.05E + 00 1.00E + 00 6.23E + 00 8.62E − 01 5.63E + 00 7.68E − 01
Gallbladder wall 1.65E + 02 8.76E + 01 1.48E + 02 8.19E + 01 1.43E + 02 8.02E + 01 1.39E + 02 7.86E + 01
LLI wall 3.19E + 01 1.09E + 01 2.96E + 01 1.05E + 01 2.78E + 01 1.02E + 01 2.65E + 01 9.91E + 00
Small intestine 7.10E + 01 3.09E + 01 6.81E + 01 3.03E + 01 6.55E + 01 2.96E + 01 6.36E + 01 2.92E + 01
Stomach wall 2.24E + 01 2.31E + 01 1.31E + 01 9.96E − 01 1.17E + 01 8.99E − 01 1.06E + 01 8.34E − 01
ULI wall 7.52E + 01 3.99E + 01 7.80E + 01 3.52E + 01 7.44E + 01 3.42E + 01 7.17E + 01 3.33E + 01
Heart wall 1.72E + 01 2.06E + 00 1.48E + 01 1.81E + 00 1.27E + 01 1.86E + 00 1.15E + 01 1.67E + 00
Kidneys 1.67E + 01 1.45E + 00 1.45E + 01 1.17E + 00 1.30E + 01 1.11E + 00 1.18E + 01 1.02E + 00
Liver 8.59E + 01 2.94E + 01 7.40E + 01 2.48E + 01 6.44E + 01 2.21E + 01 5.77E + 01 1.98E + 01
Lungs 1.10E + 01 9.93E − 01 9.58E + 00 8.91E − 01 8.52E + 00 8.01E − 01 7.73E + 00 7.21E − 01
Muscle 1.11E + 01 1.06E + 00 9.70E + 00 8.76E − 01 8.62E + 00 7.59E − 01 7.82E + 00 6.79E − 01
Ovaries 2.20E + 01 5.15E + 00 1.97E + 01 4.79E + 00 1.76E + 01 4.32E + 00 1.61E + 01 3.96E + 00
Pancreas 1.90E + 01 2.91E + 00 1.61E + 01 1.42E + 00 1.44E + 01 1.35E + 00 1.31E + 01 1.24E + 00
Red marrow 1.96E + 01 2.24E + 00 1.65E + 01 1.96E + 00 1.43E + 01 1.76E + 00 1.27E + 01 1.63E + 00
Osteogenic cells 4.01E + 01 4.90E + 00 3.27E + 01 4.21E + 00 2.76E + 01 3.71E + 00 2.40E + 01 3.34E + 00
Skin 7.75E + 00 1.11E + 00 6.70E + 00 9.32E − 01 5.92E + 00 8.06E − 01 5.34E + 00 7.15E − 01
Spleen 1.19E + 01 2.21E + 00 1.00E + 01 1.14E + 00 8.90E + 00 9.80E − 01 8.07E + 00 8.85E − 01
Testes 8.84E + 00 1.70E + 00 7.68E + 00 1.47E + 00 6.81E + 00 1.29E + 00 6.16E + 00 1.16E + 00
Thymus 9.44E + 00 1.64E + 00 8.19E + 00 1.39E + 00 7.26E + 00 1.21E + 00 6.57E + 00 1.09E + 00
Thyroid 8.79E + 00 1.90E + 00 7.61E + 00 1.62E + 00 6.75E + 00 1.43E + 00 6.10E + 00 1.28E + 00
Urinary bladder wall 3.10E + 01 1.25E + 01 2.88E + 01 1.21E + 01 2.71E + 01 1.17E + 01 2.58E + 01 1.14E + 01
Uterus 1.97E + 01 3.84E + 00 1.74E + 01 3.55E + 00 1.56E + 01 3.19E + 00 1.42E + 01 2.96E + 00
Total body 1.50E + 01 1.14E + 00 1.30E + 01 1.02E + 00 1.16E + 01 9.43E − 01 1.05E + 01 8.76E − 01
Effective dose 2.37E + 01 5.50E + 00 2.06E + 01 4.55E + 00 1.86E + 01 4.26E + 00 1.72E + 01 4.04E + 00


















Table 5 Comparison of ED (adult phantom model)
estimates for florbetapir F 18 and other 18F-labeled
pharmaceuticals
Tracer ED (μSv/MBq)
Florbetapir F 18 18.60
Flutemetamol [18F-GE067] [17] 33.8
Florbetaben [18F-BAY94-9172] [18] 14.7
18F-FDG [15] 19.0
11C-PIB [18] 5.29
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and 3 summarizes average organ dosimetry for nine
subjects with different urinary bladder voiding models.
Data for both voiding models shows that the organs
that received the highest radiation absorbed dose were
the gallbladder, upper large intestine, small intestine,
liver, and urinary bladder at 143.0 ± 80.20, 74.50 ± 34.20,
65.50 ± 29.60, 64.40 ± 22.10, and 27.10 ± 11.70 μSv/MBq,
respectively.
The organ volume, organ mass, and whole body mass
were selected and scaled [15] by ratios to the 70-kg
reference phantom model to obtain dose estimates
for 50-, 60-, and 80-kg individuals. Average dose es-
timates for different body weights are summarized in
Table 4.Discussion
The present study was designed to provide the bio-
distribution and radiation dosimetry of florbetapir. Our
study has resulted in an ED estimate of 18.6 ± 4.26 μSv/
MBq or 6.88 mSv for 370 MBq for PET. We found that
florbetapir is rapidly distributed throughout the body
shortly following I.V. administration. The gallbladder
was the organ that received the highest absorbed dose,
with an average value of 143.0 ± 80.20 μSv/MBq across
nine healthy volunteers. Variability in gallbladder activ-
ity was observed, which is possibly related to differences
in the individual kinetics of gallbladder emptying or dif-
ferences across subjects in the timing of food consump-
tion or diet. Images over time show that elimination
occurs primarily by way of clearance from the liver and
excretion through the gallbladder into the GI tract.
Some accumulation is also observed in the urinary
bladder. Modeling urinary bladder voiding at 90 min
post-injection did not substantially change the radi-
ation dosimetry results.
The present findings are very similar to the results of
a preliminary study [16] that calculated an effective
dose of 19.3 ±1.30 μSv/MBq in three subjects from an
Asian population and evaluated the organ kinetics over
a shorter (3 h) time period. In the present study, theradiation dosimetry of florbetapir was studied in nine
healthy volunteers from an American population and
the organ kinetics were evaluated for approximately 6 h.
Radiation dosimetry of other 18F-labeled PET amyloid
tracers has been evaluated by a methodology similar to
that of the present study. Koole et al. [17] and O'Keefe
et al. [18] previously studied 18F-GE067 (flutemetamol)
and 18F-BAY94-9172 (florbetaben) radiation dosime-
tries, respectively. O'Keefe et al. [18] also reported the
radiation dose estimate for the 11C-labeled PET amyl-
oid tracer 11C-PIB. The International Commission on
Radiological Protection (ICRP), in its Publication 106
[15], presents tables of 18F-fluorodeoxyglucose (18F-
FDG) and reports the effective dose. The ICRP authors
derived a kinetic model based on the data published by
Hays and Segall [19], Deloar et al. [20], and Meija et al.
[21]. The retention in the specified source organs was
considered to be infinite. The ED calculated for florbe-
tapir, flutemetamol [18F-GE067], florbetaben [18F-
BAY94-9172], 18F-FDG, and 11C-PIB are summarized
in Table 5.Conclusions
The radiation dosimetry for the 18F-labeled amyloid
imaging agent florbetapir has been calculated in nine
healthy volunteers and results in an effective radi-
ation dose of 18.60 ± 4.26 μSv/MBq or 6.88 mSv for
370 MBq.
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